ArticleTransfusion2017
Antibodies to biotinylated red blood cells in adults and infants: improved detection, partial characterization, and dependence on red blood cell-biotin dose.
Article in Transfusion, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00731588 (Red Blood Cell Survival Following Transfusion in Infants), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Red Blood Cell Survival Following Transfusion in Infants
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Red blood cell transfusion survival in sickle cell disease is reduced by donor characteristics and recipient spleen activity.Blood advances · 2026Trial
- Optimization of biotinylation protocol for next generation studies of red blood cell survival after transfusion.Transfusion · 2025Article
- A novel acridine flow cytometry marker to track post-transfusion amustaline/glutathione pathogen-reduced red blood cell survival in sickle cell disease patients.Transfusion · 2025Article
- Post-transfusion biotin-labeled red blood cell survival studies in pediatric sickle cell disease with antibodies of uncertain significance.Transfusion · 2024Article
- Optimizing interpretation of survival studies of fresh and aged transfused biotin-labeled RBCs.Transfusion · 2023Article
- Antibodies against biotin-labeled red blood cells can shorten posttransfusion survival.Transfusion · 2022Article
- Neonatal Umbilical Arterial Catheter Removal Is Accompanied by a Marked Decline in Phlebotomy Blood Loss.Neonatology · 2020Article
- Biotinylation of platelets for transfusion purposes a novel method to label platelets in a closed system.Transfusion · 2019Article
- Nix-mediated mitophagy regulates platelet activation and life span.Blood advances · 2019Article
- Improved quantitative detection of biotin-labeled red blood cells by flow cytometry.Transfusion · 2019Article
- Current good manufacturing practices-compliant manufacture and measurement of biotin-labeled red blood cells.Cytotherapy · 2019Article
- Review
- Jack Widness: the importance of connections.Pediatric research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 3 countries.
Funding
Abstract
backgroundBiotin-labeled red blood cells (BioRBCs) are used for in vivo kinetic studies. Because BioRBC dosing occasionally induces antibodies, a sensitive and specific anti-BioRBC detection assay is needed. STUDY DESIGN AND
methodsAims were to 1) develop a gel card assay to evaluate existing, naturally occurring and BioRBC-induced plasma antibodies, 2) compare gel card and tube agglutination detection results, and 3) test for a relationship of antibody induction and BioRBC dose. Reagent BioRBCs were prepared using sulfo-NHS biotin ranging from densities 18 (BioRBC-18) to 1458 (BioRBC-1458) µg/mL RBCs.
resultsAmong BioRBC-exposed subjects, gel card and tube agglutination results were concordant in 21 of 22 adults and all 19 infant plasma samples. Gel card antibody detection sensitivity was more than 10-fold greater than tube agglutination. Twelve to 16 weeks after BioRBC exposure, induced anti-antibodies were detected by gel card in three of 26 adults (12%) at reagent densities BioRBC-256 or less, but in none of 41 infants. Importantly, induced anti-BioRBC antibodies were associated with higher BioRBC dose (p = 0.008); no antibodies were detected in 18 subjects who received BioRBC doses less than or equal to BioRBC-18. For noninduced BioRBC antibodies, six of 1125 naïve adults (0.3%) and none of 46 naïve infants demonstrated existing anti-BioRBC antibodies using reagent BioRBC-140 or -162. Existing anti-BioRBCs were all neutralized by biotin compounds, while induced antibodies were not.
conclusionsThe gel card assay is more sensitive than the tube agglutination assay. We recommend reagent BioRBC-256 for identifying anti-BioRBCs. Use of a low total RBC biotin label dose (≤ BioRBC-18) may minimize antibody induction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.